Cargando…

Eosinophilic Fasciitis: Current and Remaining Challenges

Eosinophilic fasciitis (EF), defined as diffuse fasciitis with eosinophilia by Shulman in 1974, is a disease with unknown etiology and whose pathogenesis is still being researched. The diagnosis is based on the clinical aspects (skin induration with an “orange peel” appearance), the lab results (eos...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazilu, Diana, Boltașiu (Tătaru), Laura Alina, Mardale, Denise-Ani, Bijă, Maria Silviana, Ismail, Sermina, Zanfir, Violeta, Negoi, Florentina, Balanescu, Andra Rodica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916848/
https://www.ncbi.nlm.nih.gov/pubmed/36768300
http://dx.doi.org/10.3390/ijms24031982
_version_ 1784886225975377920
author Mazilu, Diana
Boltașiu (Tătaru), Laura Alina
Mardale, Denise-Ani
Bijă, Maria Silviana
Ismail, Sermina
Zanfir, Violeta
Negoi, Florentina
Balanescu, Andra Rodica
author_facet Mazilu, Diana
Boltașiu (Tătaru), Laura Alina
Mardale, Denise-Ani
Bijă, Maria Silviana
Ismail, Sermina
Zanfir, Violeta
Negoi, Florentina
Balanescu, Andra Rodica
author_sort Mazilu, Diana
collection PubMed
description Eosinophilic fasciitis (EF), defined as diffuse fasciitis with eosinophilia by Shulman in 1974, is a disease with unknown etiology and whose pathogenesis is still being researched. The diagnosis is based on the clinical aspects (skin induration with an “orange peel” appearance), the lab results (eosinophilia, increased inflammatory markers), the skin biopsy with the pathognomonic histopathological result, as well as the typical MRI changes. The treatment includes glucocorticoids and immunosuppressive drugs. Due to severe refractory cases, the treatment remains a challenge. EF is still a disease with potential for further research.
format Online
Article
Text
id pubmed-9916848
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99168482023-02-11 Eosinophilic Fasciitis: Current and Remaining Challenges Mazilu, Diana Boltașiu (Tătaru), Laura Alina Mardale, Denise-Ani Bijă, Maria Silviana Ismail, Sermina Zanfir, Violeta Negoi, Florentina Balanescu, Andra Rodica Int J Mol Sci Review Eosinophilic fasciitis (EF), defined as diffuse fasciitis with eosinophilia by Shulman in 1974, is a disease with unknown etiology and whose pathogenesis is still being researched. The diagnosis is based on the clinical aspects (skin induration with an “orange peel” appearance), the lab results (eosinophilia, increased inflammatory markers), the skin biopsy with the pathognomonic histopathological result, as well as the typical MRI changes. The treatment includes glucocorticoids and immunosuppressive drugs. Due to severe refractory cases, the treatment remains a challenge. EF is still a disease with potential for further research. MDPI 2023-01-19 /pmc/articles/PMC9916848/ /pubmed/36768300 http://dx.doi.org/10.3390/ijms24031982 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mazilu, Diana
Boltașiu (Tătaru), Laura Alina
Mardale, Denise-Ani
Bijă, Maria Silviana
Ismail, Sermina
Zanfir, Violeta
Negoi, Florentina
Balanescu, Andra Rodica
Eosinophilic Fasciitis: Current and Remaining Challenges
title Eosinophilic Fasciitis: Current and Remaining Challenges
title_full Eosinophilic Fasciitis: Current and Remaining Challenges
title_fullStr Eosinophilic Fasciitis: Current and Remaining Challenges
title_full_unstemmed Eosinophilic Fasciitis: Current and Remaining Challenges
title_short Eosinophilic Fasciitis: Current and Remaining Challenges
title_sort eosinophilic fasciitis: current and remaining challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916848/
https://www.ncbi.nlm.nih.gov/pubmed/36768300
http://dx.doi.org/10.3390/ijms24031982
work_keys_str_mv AT maziludiana eosinophilicfasciitiscurrentandremainingchallenges
AT boltasiutatarulauraalina eosinophilicfasciitiscurrentandremainingchallenges
AT mardaledeniseani eosinophilicfasciitiscurrentandremainingchallenges
AT bijamariasilviana eosinophilicfasciitiscurrentandremainingchallenges
AT ismailsermina eosinophilicfasciitiscurrentandremainingchallenges
AT zanfirvioleta eosinophilicfasciitiscurrentandremainingchallenges
AT negoiflorentina eosinophilicfasciitiscurrentandremainingchallenges
AT balanescuandrarodica eosinophilicfasciitiscurrentandremainingchallenges